Drug Profile
Research programme: therapeutic HPV vaccines - ProMed Biosciences
Latest Information Update: 12 Sep 2023
Price :
$50
*
At a glance
- Originator Profectus Biosciences
- Class Cancer vaccines; Papillomavirus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Human papillomavirus infections
Most Recent Events
- 12 Sep 2023 Discontinued - Preclinical for Human papillomavirus infections (Adjunctive treatment) in USA (Parenteral)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Human-papillomavirus-infections(Adjunctive treatment) in USA (Parenteral)
- 17 May 2018 Profectus Biosciences and Promed Biosciences enter into a licensing agreement to develop, manufacture, and commercialise Profectus’ vaccine to treat HPV-associated lesions